Rationale, design, and methods of a non-interventional study to establish safety, effectiveness, quality of life, cognition, health-related and work capacity data on Alemtuzumab in multiple sclerosis patients in Germany (TREAT-MS)

BackgroundAlemtuzumab, a humanized monoclonal antibody directed against the cell surface glycoprotein CD52, is licensed in Europe since October 2013 as treatment for adult patients with active relapsing-remitting multiple sclerosis (RRMS). In three randomized, rater-blinded active comparator clinical trials studies, alemtuzumab administered in two annual courses, had superior efficacy as compared to subcutaneous interferon beta-1a, and durable efficacy over 5 years in an extension study with a manageable safety profile in RRMS patients. Data on the utilization and the outcomes of alemtuzumab under clinical practice conditions are limited.MethodsHere we describe the rationale, design and methods of the TREAT-MS study (non-interventional long-Term study foR obsErvAtion of Treatment with alemtuzumab in active relapsing-remitting MS).DiscussionTREAT-MS is a prospective, multicenter, non-interventional, long-term study to collect data on safety, effectiveness, quality of life, cognition and other aspects from 3200 RRMS patients treated with alemtuzumab under the conditions of real-world clinical practice in Germany.Trial registrationAs non-interventional trial in Germany.

[1]  K. Selmaj,et al.  Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. , 2008, The New England journal of medicine.

[2]  H. Wiendl,et al.  Simultaneous early-onset immune thrombocytopenia and autoimmune thyroid disease following alemtuzumab treatment in relapsing-remitting multiple sclerosis , 2016, Multiple sclerosis.

[3]  L. Doward,et al.  The development of patient-reported outcome indices for multiple sclerosis (PRIMUS) , 2009, Multiple sclerosis.

[4]  A. Coles,et al.  Mode of action and clinical studies with alemtuzumab , 2014, Experimental Neurology.

[5]  M. Comabella,et al.  Teriflunomide in Patients with Relapsing–Remitting Forms of Multiple Sclerosis , 2016, CNS Drugs.

[6]  A. Coles,et al.  Case report of anti-glomerular basement membrane disease following alemtuzumab treatment of relapsing-remitting multiple sclerosis. , 2013, Multiple sclerosis and related disorders.

[7]  P. Gallo,et al.  Overview of the management of relapsing−remitting multiple sclerosis and practical recommendations , 2015, European journal of neurology.

[8]  D. Rothenbacher,et al.  New opportunities of real-world data from clinical routine settings in life-cycle management of drugs: example of an integrative approach in multiple sclerosis , 2015, Current medical research and opinion.

[9]  Raimar Kern,et al.  Study design of PANGAEA 2.0, a non-interventional study on RRMS patients to be switched to fingolimod , 2016, BMC Neurology.

[10]  F. Paul,et al.  The Transition From First-Line to Second-Line Therapy in Multiple Sclerosis , 2015, Current Treatment Options in Neurology.

[11]  L. Kappos,et al.  On the origin of Neurostatus. , 2015, Multiple sclerosis and related disorders.

[12]  M. Sormani,et al.  Optimizing therapy early in multiple sclerosis: An evidence-based view. , 2015, Multiple sclerosis and related disorders.

[13]  A. Zbrozek,et al.  The Validity and Reproducibility of a Work Productivity and Activity Impairment Instrument , 1993, PharmacoEconomics.

[14]  H. Reichmann,et al.  New insights into the pharmacokinetics and pharmacodynamics of natalizumab treatment for patients with multiple sclerosis, obtained from clinical and in vitro studies , 2016, Journal of Neuroinflammation.

[15]  M. Wattjes,et al.  Guidelines on PML risk stratification and diagnosis in patients with MS treated with natalizumab: so far so good? , 2015, Journal of Neurology, Neurosurgery & Psychiatry.

[16]  A. Compston,et al.  Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy , 2014, Journal of Neurology, Neurosurgery & Psychiatry.

[17]  F. Maura,et al.  Low‐dose alemtuzumab‐associated immune thrombocytopenia in chronic lymphocytic leukemia , 2012, American journal of hematology.

[18]  A. Thompson,et al.  A Predictive Model for Corticosteroid Response in Individual Patients with MS Relapses , 2015, PloS one.

[19]  Raimar Kern,et al.  The PANGAEA study design – a prospective, multicenter, non-interventional, long-term study on fingolimod for the treatment of multiple sclerosis in daily practice , 2015, BMC Neurology.

[20]  T. Ziemssen,et al.  Management of fingolimod in clinical practice , 2013, Clinical Neurology and Neurosurgery.

[21]  M. Freedman,et al.  Insights into the Mechanisms of the Therapeutic Efficacy of Alemtuzumab in Multiple Sclerosis. , 2013, Journal of clinical & cellular immunology.

[22]  Christian Confavreux,et al.  Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial , 2012, The Lancet.

[23]  H. Wiendl,et al.  Multiple sclerosis: reprogramming the immune repertoire with alemtuzumab in MS. , 2013, Nature reviews. Neurology.

[24]  Jan Hillert,et al.  The importance of collecting structured clinical information on multiple sclerosis , 2016, BMC Medicine.

[25]  L. Kappos,et al.  Onset of clinical and MRI efficacy occurs early after fingolimod treatment initiation in relapsing multiple sclerosis , 2015, Journal of Neurology.

[26]  B. Uitdehaag.  Clinical outcome measures in multiple sclerosis. , 2014, Handbook of clinical neurology.

[27]  L. Kappos,et al.  MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis , 2006, Multiple sclerosis.

[28]  H. Reichmann,et al.  [Multiple sclerosis management system 3D. Moving from documentation towards management of patients]. , 2012, Der Nervenarzt.

[29]  H. Wiendl,et al.  Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond , 2015, International journal of molecular sciences.

[30]  F. Barkhof,et al.  MRI characteristics of early PML-IRIS after natalizumab treatment in patients with MS , 2015, Journal of Neurology, Neurosurgery & Psychiatry.

[31]  T. Derfuss,et al.  Optimizing treatment success in multiple sclerosis , 2015, Journal of Neurology.

[32]  J. Berger,et al.  Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis , 2013, Current Neurology and Neuroscience Reports.

[33]  E. Leray,et al.  Alemtuzumab as rescue therapy in a cohort of 16 aggressive multiple sclerosis patients previously treated by Mitoxantrone: an observational study , 2015, Journal of Neurology.

[34]  F. Deisenhammer,et al.  Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial , 2012, Neurology.

[35]  T. Ziemssen,et al.  Therapy satisfaction and adherence in patients with relapsing–remitting multiple sclerosis: the THEPA-MS survey , 2016, Therapeutic advances in neurological disorders.

[36]  H. Sullivan,et al.  Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 Clinical Trial , 2012, Neurology.

[37]  E. Havrdová,et al.  Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use , 2015, Therapeutic advances in neurological disorders.

[38]  Amanda L. Cox,et al.  Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis , 2005, European journal of immunology.

[39]  Raimar Kern,et al.  Designing an Electronic Patient Management System for Multiple Sclerosis: Building a Next Generation Multiple Sclerosis Documentation System , 2016, Interactive journal of medical research.

[40]  H. Sullivan,et al.  A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis. , 2011, Blood.

[41]  Raimar Kern,et al.  Multiple sclerosis: clinical profiling and data collection as prerequisite for personalized medicine approach , 2016, BMC Neurology.

[42]  Meena Subramanyam,et al.  Risk of natalizumab-associated progressive multifocal leukoencephalopathy. , 2012, The New England journal of medicine.

[43]  L. Hofbauer,et al.  Graves’ disease after treatment with Alemtuzumab for multiple sclerosis , 2002, Hormones.

[44]  G. Cordeiro,et al.  Progressive multifocal leukoencephalopathy in a patient with chronic lymphocytic leukaemia treated with alemtuzumab , 2014, BMJ Case Reports.

[45]  J. Kurtzke.  Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[46]  R. Zivadinov,et al.  Time for change - Evolution of real-world evidence outcome measures in multiple sclerosis exemplified by fingolimod , 2015 .

[47]  Achim Gass,et al.  Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab , 2016, BMC Neurology.

[48]  Tjalf Ziemssen,et al.  Mehr als dokumentieren: computerunterstütztes Patientenmanagement , 2013, DNP - Der Neurologe und Psychiater.

[49]  Aki Tsuchiya,et al.  A single European currency for EQ-5D health states , 2003, The European Journal of Health Economics, formerly: HEPAC.

[50]  T. Ziemssen,et al.  Acute effects of alemtuzumab infusion in patients with active relapsing-remitting MS , 2016, Neurology: Neuroimmunology & Neuroinflammation.

[51]  T. Ziemssen,et al.  Hands on Alemtuzumab-experience from clinical practice: whom and how to treat , 2016, Multiple Sclerosis and Demyelinating Disorders.

[52]  B. Hemmer,et al.  Current treatment strategies for multiple sclerosis - efficacy versus neurological adverse effects. , 2012, Current pharmaceutical design.

[53]  F. Bagnato,et al.  Alemtuzumab for the treatment of multiple sclerosis , 2018, Expert opinion on biological therapy.

[54]  Jeffrey A. Cohen,et al.  Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial , 2012, The Lancet.

[55]  Alexander Suhrbier,et al.  Multiple sclerosis documentation system (MSDS): moving from documentation to management of MS patients , 2013, Journal of Neural Transmission.

[56]  Martin S. Weber,et al.  The Use of Oral Disease-Modifying Therapies in Multiple Sclerosis , 2016, Current Neurology and Neuroscience Reports.

[57]  T. Kohlmann,et al.  International development of the patient-reported outcome indices for multiple sclerosis (PRIMUS). , 2010, Value in Health.

[58]  H. Hartung,et al.  Alemtuzumab: A new therapy for active relapsing–remitting multiple sclerosis , 2015, Multiple sclerosis.

[59]  R. Rabin,et al.  EQ-SD: a measure of health status from the EuroQol Group , 2001, Annals of medicine.

[60]  L. Weiner,et al.  Therapeutic decisions in multiple sclerosis: moving beyond efficacy. , 2013, JAMA neurology.

[61]  M. Pette,et al.  [The Multiple Sclerosis Documentation System MSDS. Discussion of a documentation standard for multiple sclerosis]. , 2002, Der Nervenarzt.

[62]  M. Eulitz,et al.  Das Multiple-Sklerose-Dokumentationssystem MSDS Diskussionsgrundlage für einen Dokumentationsstandard Multiple Sklerose? , 2002, Der Nervenarzt.